Healthcare >> Analyst Interviews >> February 4, 2002

Drug Development & Biotechnology Companies: Ken Trbovich – C.e. Untergerg, Towbin

KEN TRBOVICH is a Vice President in equity research for C.E. Unterberg, Towbin. He has seven years' experience researching and analyzing US public companies, including three years exclusively focused on coverage of small-and mid-capitalization drug development and specialty pharmaceutical companies. The latter includes coverage of late-stage (Phase III clinical trials) biotechnology companies, firms developing new formulations of existing products to protect brands from generic substitution, and corporations attempting to expand the market for currently approved products through clinical studies of new indications. His education includes a BSBA in Accounting from the University of Arizona and a Master's from Thunderbird (American Graduate School of International Management). He is also a CFA charterholder. Profile
TWST: Will you begin by telling us about the life sciences biotechnology

research effort at C.E. Unterberg, Towbin and, more specifically, about

your particular focus in the sector?